Charles Schwab’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $164M | Buy |
974,279
+71,491
| +8% | +$10.6M | 0.02% | 536 |
|
|
2026
Q1 | $119M | Buy |
902,788
+52,156
| +6% | +$6.92M | 0.02% | 640 |
|
|
2025
Q4 | $121M | Buy |
850,632
+21,085
| +3% | +$3.05M | 0.02% | 633 |
|
|
2025
Q3 | $116M | Buy |
829,547
+39,832
| +5% | +$5.4M | 0.02% | 632 |
|
|
2025
Q2 | $99.3M | Buy |
789,715
+13,942
| +2% | +$1.6M | 0.02% | 683 |
|
|
2025
Q1 | $85.8M | Buy |
775,773
+13,216
| +2% | +$1.67M | 0.02% | 727 |
|
|
2024
Q4 | $104M | Buy |
762,557
+15,266
| +2% | +$1.89M | 0.02% | 646 |
|
|
2024
Q3 | $86.1M | Sell |
747,291
-5,210
| -0.7% | -$714K | 0.02% | 754 |
|
|
2024
Q2 | $104M | Buy |
752,501
+27,323
| +4% | +$3.75M | 0.02% | 633 |
|
|
2024
Q1 | $100M | Buy |
725,178
+38,343
| +6% | +$5.24M | 0.02% | 603 |
|
|
2023
Q4 | $90.5M | Buy |
686,835
+63,568
| +10% | +$7.32M | 0.02% | 608 |
|
|
2023
Q3 | $70.1M | Buy |
623,267
+18,334
| +3% | +$1.93M | 0.02% | 684 |
|
|
2023
Q2 | $57M | Buy |
604,933
+20,541
| +4% | +$2.01M | 0.02% | 785 |
|
|
2023
Q1 | $59.2M | Buy |
584,392
+18,353
| +3% | +$1.91M | 0.02% | 724 |
|
|
2022
Q4 | $67.6M | Buy |
566,039
+25,063
| +5% | +$2.94M | 0.02% | 635 |
|
|
2022
Q3 | $57.5M | Buy |
540,976
+7,975
| +1% | +$809K | 0.02% | 677 |
|
|
2022
Q2 | $52M | Buy |
533,001
+12,152
| +2% | +$1.12M | 0.02% | 730 |
|
|
2022
Q1 | $48.8M | Buy |
520,849
+11,234
| +2% | +$952K | 0.01% | 885 |
|
|
2021
Q4 | $43.4M | Buy |
509,615
+12,547
| +3% | +$1.15M | 0.01% | 996 |
|
|
2021
Q3 | $47.7M | Buy |
497,068
+17,419
| +4% | +$1.65M | 0.02% | 906 |
|
|
2021
Q2 | $46.7M | Buy |
479,649
+12,579
| +3% | +$1.21M | 0.02% | 923 |
|
|
2021
Q1 | $45.4M | Sell |
467,070
-7,451
| -2% | -$781K | 0.02% | 904 |
|
|
2020
Q4 | $45.5M | Buy |
474,521
+3,989
| +0.8% | +$385K | 0.02% | 824 |
|
|
2020
Q3 | $45.2M | Buy |
470,532
+8,050
| +2% | +$931K | 0.02% | 708 |
|
|
2020
Q2 | $56.4M | Buy |
462,482
+10,453
| +2% | +$1.16M | 0.03% | 572 |
|
|
2020
Q1 | $39.1M | Buy |
452,029
+10,552
| +2% | +$1.03M | 0.02% | 622 |
|
|
2019
Q4 | $47.5M | Buy |
441,477
+8,420
| +2% | +$882K | 0.03% | 663 |
|
|
2019
Q3 | $39M | Buy |
433,057
+31,520
| +8% | +$2.94M | 0.02% | 723 |
|
|
2019
Q2 | $33.9M | Buy |
401,537
+15,588
| +4% | +$1.28M | 0.02% | 794 |
|
|
2019
Q1 | $34M | Buy |
385,949
+26,503
| +7% | +$2.22M | 0.02% | 770 |
|
|
2018
Q4 | $25.7M | Buy |
359,446
+14,216
| +4% | +$1.36M | 0.02% | 828 |
|
|
2018
Q3 | $42.4M | Sell |
345,230
-127,057
| -27% | -$14.4M | 0.03% | 614 |
|
|
2018
Q2 | $46.4M | Buy |
472,287
+32,769
| +7% | +$2.93M | 0.03% | 540 |
|
|
2018
Q1 | $36.5M | Buy |
439,518
+29,996
| +7% | +$2.53M | 0.03% | 627 |
|
|
2017
Q4 | $31.8M | Buy |
409,522
+25,834
| +7% | +$1.76M | 0.03% | 663 |
|
|
2017
Q3 | $23.5M | Buy |
383,688
+22,441
| +6% | +$1.18M | 0.02% | 803 |
|
|
2017
Q2 | $16.6M | Buy |
361,247
+14,341
| +4% | +$696K | 0.02% | 996 |
|
|
2017
Q1 | $15M | Buy |
346,906
+27,245
| +9% | +$1.17M | 0.02% | 1019 |
|
|
2016
Q4 | $12.4M | Buy |
319,661
+23,540
| +8% | +$1.07M | 0.01% | 1099 |
|
|
2016
Q3 | $15M | Buy |
296,121
+41,545
| +16% | +$2.07M | 0.02% | 880 |
|
|
2016
Q2 | $11.6M | Sell |
254,576
-141,394
| -36% | -$6.51M | 0.01% | 979 |
|
|
2016
Q1 | $15.7M | Buy |
395,970
+63,804
| +19% | +$2.53M | 0.02% | 758 |
|
|
2015
Q4 | $18.8M | Buy |
332,166
+16,312
| +5% | +$829K | 0.03% | 627 |
|
|
2015
Q3 | $12.6M | Buy |
315,854
+68,109
| +27% | +$3.29M | 0.02% | 834 |
|
|
2015
Q2 | $11.8M | Buy |
247,745
+7,508
| +3% | +$318K | 0.02% | 901 |
|
|
2015
Q1 | $9.54M | Buy |
240,237
+29,098
| +14% | +$1.04M | 0.01% | 1025 |
|
|
2014
Q4 | $4.72M | Buy |
211,139
+6,946
| +3% | +$132K | 0.01% | 1493 |
|
|
2014
Q3 | $3.2M | Buy |
204,193
+4,174
| +2% | +$62.4K | 0.01% | 1692 |
|
|
2014
Q2 | $2.97M | Buy |
200,019
+12,388
| +7% | +$175K | 0.01% | 1746 |
|
|
2014
Q1 | $3.02M | Buy |
187,631
+4,892
| +3% | +$83.7K | 0.01% | 1708 |
|
|
2013
Q4 | $1.71M | Buy |
182,739
+17,148
| +10% | +$167K | ﹤0.01% | 2011 |
|
|
2013
Q3 | $1.92M | Buy |
165,591
+7,574
| +5% | +$104K | ﹤0.01% | 1864 |
|
|
2013
Q2 | $2.15M | Buy |
+158,017
| New | +$1.94M | ﹤0.01% | 1716 |
|
Other funds holding NBIX
Charles Schwab's NBIX Position: Q2 2026 in Review
Charles Schwab increased its Neurocrine Biosciences (NBIX) stake by 7.9% in Q2 2026, buying an estimated $10.6M and bringing the position to 974,279 shares worth $164M. The position accounts for 0.02% of the portfolio, ranked #536.
Charles Schwab first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Charles Schwab held 974,279 shares of Neurocrine Biosciences worth $164M as of Q2 2026.
- Charles Schwab bought 71,491 Neurocrine Biosciences shares in Q2 2026, an estimated $10.6M.
- Neurocrine Biosciences made up 0.02% of Charles Schwab's portfolio in Q2 2026, its #536 holding.
- Charles Schwab first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.